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Clinical trials investigating the safety and effectiveness of
transcatheter leadless pacemakers in humans are ongoing.1,2
These devices offer the beneﬁts of cardiac pacing with the
potential for a signiﬁcant decrease in many of the risks
associated with conventional pacing systems, including
hematoma formation, pneumothorax, lead-related complica-
tions, and vascular obstruction.3
Human evaluation of the Medtronic Micra Transcatheter
Pacing System (Medtronic, Minneapolis, MN) began in
2013, and the device is currently undergoing clinical inves-
tigation.1 The devices are implanted via a femoral venous
approach and use a novel tined system for ﬁxation to the
right ventricular endocardium. The pacemakers can be
readily retrieved at the time of implantation, but no data
exist regarding the ability to remove these devices in humans
after the initial implantation procedure. We report the ﬁrst
successful extraction of a Micra Transcatheter Pacing
System, 3 weeks after initial device implantation.Case report
A 61-year-old man developed dizziness and near syncope in
the setting of permanent atrial ﬁbrillation. Evaluation
revealed a persistently slow ventricular response (30–40
beats per minute). He subsequently underwent transcatheter
leadless pacemaker implantation, as part of the Micra trans-
catheter pacing study. The implantation was uncomplicated
and he was discharged from the hospital with stable pacing
(sensing at 8 mV, pacing threshold of 0.63 V at 0.24 ms and
impedance of 650 ohms). He returned to the clinic 15 days
later, noting a several-day history of dizziness and fatigue.
An electrocardiogram demonstrated atrial ﬁbrillation with a
slow ventricular response as well as noncaptured pacing
impulses. His device was interrogated and an elevatedKEYWORDS Leadless pacemaker; Extraction
ABBREVIATIONS RV ¼ right ventricle
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).capture threshold was noted (5 V at 1.0 ms). The automated
capture management algorithm had appropriately monitored
the threshold and increased the pacing output signiﬁcantly
(5.0 V at 1.0 ms). Sensing and impedance parameters were
stable. A chest radiograph demonstrated stable device
position. The pacing output was increased and he was
admitted to the hospital. As battery longevity would be
curtailed at high pacing outputs, the decision was made to
replace the pacing system.
He was subsequently brought to the Electrophysiology
laboratory for device extraction and replacement. The initial
plan was to place a second transcatheter leadless pacemaker
at a remote site in the right ventricle (RV) and use the
delivery system for the second device to recapture and
remove the ﬁrst device. The Medtronic Micra sheath
(Medtronic, Minneapolis, MN) was placed in the right
femoral vein and the Micra delivery system was used to
advance a new transcatheter leadless pacemaker to the RV. It
was difﬁcult to ﬁnd a suitable right ventricular site for the
second pacemaker that elicited acceptable electrical values
and was sufﬁciently removed from the initial implantation
site. After a number of attempts, this approach was aban-
doned and the delivery system was removed.
A 6F sheath was placed in the left femoral vein and a 5F
quadripolar catheter (Bard, Lowell, MA) was advanced to
the RV, to provide backup pacing once the initial device was
removed. Attention was then turned to extraction of the
transcatheter leadless pacemaker.
An 8.5F 28 mm medium-curve steerable sheath (Agilis
NxT; St Jude Medical, Minnetonka, MN) was advanced via
the 23F Medtronic Micra sheath to the right atrium. The
deﬂectable sheath was used to advance a foreign body
retrieval device (20 mm EN snare; Merit Medical Systems,
South Jordan, UT) with multiple loops to the RV. The
proximal retrieval feature of the device could not be engaged
with this system, but 1 of the ﬁxation tines was snared
(Figure 1). The device was removed to the right atrium but
became detached from the snare. The multiple-loop snare
was removed and a single-loop snare (Amplatz GooseNeck
Snare; Covidien/Medtronic, Plymouth, MN) was used to
attempt to capture the retrieval feature on the device.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.10.001
Figure 2 Two snares were used to capture 2 separate ﬁxation tines on the
Micra pacemaker. This allowed the device to be properly aligned so that it
could be retracted into the Micra introducer.
KEY TEACHING POINTS
 It is possible to extract the Micra leadless
pacemaker several weeks after initial implantation.
Though the device has a specialized retrieval
mechanism, it is possible to capture the device
body using a multilobed snare.
 If the device is captured without the specialized
retrieval mechanism, it may be necessary to use
several snares to align the device and facilitate
removal through the Micra introducer sheath.
61Karim et al Extraction of a Transcatheter Pacemaker SystemUltimately, 1 of the ﬁxation tines of the device was captured
with the snare. With only 1 of the 4 ﬁxation tines attached,
the device could not be properly aligned and retracted into
the introducer. A second snare (20 mm EN Snare; Merit
Medical Systems) was then advanced to the right atrium and
a second tine was snared (Figure 2). The 2 snares were used
to align the pacemaker and it was retracted into the
introducer and subsequently removed from the body
(Figure 3). The new transcatheter leadless pacemaker was
then successfully implanted to the RV.Discussion
Implantable transcatheter leadless pacemakers offer many poten-
tial advantages over conventional pacing systems, including
decreased risk of infection, pneumothorax, pocket-related issues,
and transvenous lead–related issues. However, other risks
associated with pacemaker implantation will likely remain, some
of which may necessitate device removal or revision.
Currently available delivery systems allow for the device
to be repositioned multiple times during the initial implantFigure 1 The Micra pacemaker was snared in the right ventricle using a
multilobed gooseneck snare, which captured 1 of the ﬁxation tines of the
device.procedure. However, once the device has been fully deliv-
ered, device recapture is much more challenging. The Micra
device has been designed with a proximal retrieval feature to
aid in recapture. Any ﬁxation tines that have not engaged the
endocardium are also a potential target for retrieval. We have
demonstrated that it is possible to capture the device and
successfully remove it several weeks after implantation,
using readily available foreign body removal snares.Conclusion
Despite their theoretical advantages, transcatheter lead-
less pacemakers will still occasionally require deviceFigure 3 The snares were used in tandem to properly orient the device
and allow its retraction into the Micra introducer and subsequent removal
from the body.
Heart Rhythm Case Reports, Vol 2, No 1, January 201662repositioning or removal. Few data are available
regarding the ease or feasibility of device retrieval
after implantation. Though the device is designed
with a proximal retrieval feature, we have demon-
strated that it can be safely removed with an
alternate method, using routinely available foreign
body retrieval equipment to capture the ﬁxation tines of
the device.References
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